ArticleTransfusion2013
Antibody levels correlate with detection of Trypanosoma cruzi DNA by sensitive polymerase chain reaction assays in seropositive blood donors and possible resolution of infection over time.
Article in Transfusion, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Commercial enzyme-linked immunosorbent assay versuspolymerase chain reaction for the diagnosis of chronic Chagas disease: a systematic review and meta-analysis.Memorias do Instituto Oswaldo Cruz · 2016Pooled it
- Implementation Science in the Development of a Care Pathway for Chronic Chagas Disease: An Experience from a Municipality in Minas Gerais.Revista da Sociedade Brasileira de Medicina Tropical · 2026Article
- Bimodal distributions of anti-Trypanosoma cruzi antibody levels in blood donors are associated with parasite detection and antibody waning in peripheral blood.PLoS neglected tropical diseases · 2025Article
- Diagnosis of Trypanosoma cruzi infection in Mexican populations: current conventional serology lacks adequate sensitivity and specificity.Memorias do Instituto Oswaldo Cruz · 2025Article
- Cardiac involvement in Chagas disease and African trypanosomiasis.Nature reviews. Cardiology · 2024Review
- Increased Natural Killer (NK)-cell cytotoxicity and Trypanosoma cruzi-specific memory B cells in subjects with discordant serology for Chagas disease.Biochimica et biophysica acta. Molecular basis of disease · 2024Article
- Congenital Transmission ofVector borne and zoonotic diseases (Larchmont, N.Y.) · 2023Article
- Anti-Trypanosoma cruzi antibody profiling in patients with Chagas disease treated with benznidazole assessed by genome phage display.PLoS neglected tropical diseases · 2023Article
- Accuracy of Diagnostic Tests for the Detection of Chagas Disease: A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2022Review
- A refined genome phage display methodology delineates the human antibody response in patients with Chagas disease.iScience · 2021Article
- Disagreement between PCR and serological diagnosis of Trypanosoma cruzi infection in blood donors from a Colombian endemic region.Biomedica : revista del Instituto Nacional de Salud · 2021Article
- Comparative Performance of Latest-Generation and FDA-Cleared Serology Tests for the Diagnosis of Chagas Disease.Journal of clinical microbiology · 2021Article
- A novel Trypanosoma cruzi secreted antigen as a potential biomarker of Chagas disease.Scientific reports · 2020Article
- Declining antibody levels to Trypanosoma cruzi correlate with polymerase chain reaction positivity and electrocardiographic changes in a retrospective cohort of untreated Brazilian blood donors.PLoS neglected tropical diseases · 2020Article
- Gut Dysbiosis in Chagas Disease. A Possible Link to the Pathogenesis.Frontiers in cellular and infection microbiology · 2020Article
- A Parasite Biomarker Set for Evaluating Benznidazole Treatment Efficacy in Patients with Chronic Asymptomatic Trypanosoma cruzi Infection.Antimicrobial agents and chemotherapy · 2019Article
- Lack of evidence of seronegative infection in an endemic area of Chagas disease.Revista do Instituto de Medicina Tropical de Sao Paulo · 2019Article
- Beneficial effects of benznidazole in Chagas disease: NIH SaMi-Trop cohort study.PLoS neglected tropical diseases · 2018Observational
- The Impact of Emerging Infectious Diseases on Chinese Blood Safety.Transfusion medicine reviews · 2017Review
- Chagas disease research and development: Is there light at the end of the tunnel?Computational and structural biotechnology journal · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundThe clinical significance of anti-Trypanosoma cruzi low-level reactive samples is incompletely understood. Polymerase chain reaction (PCR)-positive rates and antibody levels among seropositive blood donors in three countries are described. STUDY DESIGN AND
methodsFollow-up samples were collected from T. cruzi-seropositive donors from 2008 through 2010 in the United States (n = 195) and Honduras (n = 58). Also 143 samples from Brazil in 1996 to 2002, originally positive by three serologic assays, were available and paired with contemporary follow-up samples from these donors. All samples were retested with Ortho enzyme-linked immunosorbent assay (ELISA). PCR assays were performed on coded sample panels by two laboratories (Blood Systems Research Institute [BSRI] and American Red Cross Holland Laboratory [ARC]) that amplified kinetoplast minicircle DNA sequences of T. cruzi.
resultsPCR testing at BSRI yielded slightly higher overall sensitivity and specificity (33 and 98%) compared with those at the ARC (28 and 94%). Among seropositive donors, PCR-positive rates varied by country (p < 0.0001) for the BSRI laboratory: Brazil (57%), Honduras (32%), and the United States (14%). ELISA signal-to-cutoff ratios (S/CO) were significantly higher for PCR-positive compared to PCR-negative donors (p < 0.05 for all comparisons). Additionally, PCR-negative Brazilian donors exhibited greater frequencies of antibody decline over time versus PCR-positive donors (p = 0.003).
conclusionFor all three countries, persistent DNA positivity correlated with higher ELISA S/CO values, suggesting that high-level seroreactivity reflects chronic parasitemia. Significant S/CO declines in 10% of the PCR-negative Brazilian donors may indicate seroreversion after parasite clearance in the absence of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.